Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Lodz – page 56

1 026 clinical trials in Lodz, Poland across 18 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Lodz at a glance
1 026
clinical trials
  • Research sites18
Type of trial
Recruitment status
Quick filters

1 026 trials in Lodz

Open in trial search

Meningococcal immunisation

Not recruiting

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Diphtheria toxoid
  • Sponsor:Sanofi Pasteur Inc.

Psoriatic arthropathy+1

Not recruiting

Study on How Bimekizumab Affects People with Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Human papilloma virus immunisation

Not recruiting

Study on the Safety and Immune Response of 9vHPV Vaccine in Preventing HPV in Boys and Girls Aged 9-14 Compared to Young Women Aged 16-26

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
  • Sponsor:Merck Sharp & Dohme LLC

Spinal muscular atrophy

Not recruiting

Study on the Safety and Tolerability of BIIB115 for Children with Spinal Muscular Atrophy Previously Treated with Gene Therapy

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:BIIB115
  • Sponsor:Biogen Idec Research Limited

Respiratory syncytial virus infection

Not recruiting

Study on the Safety and Effectiveness of MK-1654 for Preventing Respiratory Syncytial Virus (RSV) in Healthy Pre-Term and Full-Term Infants

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Sponsor:Merck Sharp & Dohme LLC

Obesity+1

Not recruiting

Study on the Effects of RO7204239 and Tirzepatide for Weight Loss in Patients with Obesity or Overweight with a Weight-Related Health Issue

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tirzepatide
  • Sponsor:F. Hoffmann-La Roche AG

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Tolerability of VRDN-003 for Patients with Thyroid Eye Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003
  • Sponsor:Viridian Therapeutics Inc.

Obesity+1

Not recruiting

Study on Maridebart Cafraglutide for Adults with Type 2 Diabetes and Obesity or Overweight

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+1

Not recruiting

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Endocrine ophthalmopathy

Not recruiting

Study on the Effectiveness and Safety of VRDN-003 for Patients with Chronic Thyroid Eye Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003
  • Sponsor:Viridian Therapeutics Inc.

Hidradenitis

Not recruiting

Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Myasthenia gravis

Not recruiting

Study on the Effects of Remibrutinib for Patients with Generalized Myasthenia Gravis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Lodz

What the registry says about research in the country

01 Respiratory Research

Ongoing clinical trials focusing on respiratory viral infections and preventive vaccines, particularly targeting RSV and influenza in older adults. Studies evaluate vaccine efficacy and immune responses to protect against severe respiratory diseases.

  • RSV and Influenza Prevention
  • Vaccine Immunogenicity
  • COPD Management

Multiple studies assess combination vaccines and co-administration strategies to enhance protection against multiple respiratory pathogens.

02 Dermatological Studies

Innovative research examining treatments for plaque psoriasis and related conditions. Trials investigate novel therapeutic approaches including oral medications and biological treatments for moderate to severe cases.

  • Psoriasis Treatment
  • Hidradenitis Suppurativa
  • Inflammatory Skin Conditions

Studies focus on measuring improvement in disease severity and quality of life outcomes for patients.

03 Immunology and Vaccines

Comprehensive research on meningococcal and pneumococcal vaccines, with special attention to pediatric populations. Studies evaluate safety profiles and immune responses across different age groups.

  • Pediatric Vaccinations
  • Immune Response Assessment
  • Preventive Medicine

Trials incorporate multiple age cohorts from infants to adolescents, ensuring comprehensive vaccine effectiveness data.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.